Peficitinib 是一种可口服的 JAK 抑制剂，对 JAK1、JAK2、JAK3 和 Tyk2 的IC50值分别为 3.9、5.0、0.7 和 4.8?nM。

Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.

ASP015K suppresses the IL-2-induced proliferation of human T cells with greater potency than EPO-induced proliferation of human erythroleukemia cells. In human whole blood, ASP015K inhibits STAT5 phosphorylation (pSTAT5). [1]

In the rat AIA model, ASP015K (p.o.) significantly decreases paw swelling and ankle bone destruction score. [1]

944118-01-8

C18H22N4O2

326.4

ASP015K;JNJ-54781532

H2O:<1 mgml
Ethanol:<1 mgml
DMSO:60 mg/mL (183.8 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years